Loading…
New Era of Preventing End-Stage Kidney Disease Act
Legislative Progress
Introduced
February 24, 2025
Latest Action
February 24, 2025
Primary Sponsor
Gus M. BilirakisRepublican(FL)
Momentum (last 30 days)
4
score
0 actions · 2 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
New Era of Preventing End-Stage Kidney Disease Act This bill establishes regional centers of excellence, postgraduate fellowships, and training for health professionals relating to the diagnosis and treatment of rare kidney disease. It also requires the Department of Health and Human Services (HHS) to conduct various studies on rare kidney disease. Specifically, it authorizes the National Institute of Diabetes and Digestive and Kidney Diseases to award funding to public and private nonprofit entities for establishing regional centers of excellence that will increase public awareness, conduct research, and develop resources for diagnosing and treating rare kidney diseases. A center may receive such funding for up to five years, unless extended by the institute. The bill also requires health professions schools receiving a grant from the Health Resources and Services Administration (HRSA) Centers of Excellence program to award fellowships for training on preventing, diagnosing, and treating rare kidney disease in disproportionately impacted populations. Also, the bill expands the priorities of HRSA’s Primary Care Training and Enhancement program to include training for health care workers to care for individuals with kidney disease. Additionally, HHS must conduct several studies and report to Congress on topics such as treating rare kidney disease in disproportionately affected populations, eliminating the need for dialysis or kidney transplants, and increasing public awareness of rare kidney disease.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (9)
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Medicare/Medicaid
H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. H.R.10571, Surge to Save Newborns Act. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Access to Genetic Counselor Services Act: H.R. 6280, S. 3607 Living Donor Protection Act: H.R. 4582, H.R 4583, S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 6214 Expanding Support for Living Donors Act: H.R. 7868 Improving Home Dialysis Act: H.R. 8875 CMS-1846-P: Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury Dialysis (AKI) Payment, and ESRD Quality Incentive Program Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program Medicaid Program; Community Engagement Requirement for Certain Individuals (CMS- 2454-IFC); Interim Final Rule with Comment Period
Client expense: $220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Client expense: $1,100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Client expense: $310,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Access to Genetic Counselor Services Act: H.R. 6280, S. 3607 Living Donor Protection Act: H.R. 4582, H.R 4583, S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 6214 Expanding Support for Living Donors Act: H.R. 7868 Improving Home Dialysis Act: H.R. 8875 Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4212-P) Request for Information: Opportunities, Challenges, and Emerging Areas in Statistical Data, Analysis, and Research
Client expense: $240,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Health Issues
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Health Issues
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
-Expanding Support for Living Donors Act (H.R. 7868) Legislation to expand how much living donors can be reimbursed and to increase the threshold for income-based qualification -Living Donor Protection Act (H.R. 4583) and related FMLA bill (H.R. 4582 and S. 1552). Clarifies and strengthens protections for Americans who donate an organ. -Concurrent Care for Comfort Act (HR 8367) and related policy concepts regarding helping patients on dialysis nearing end of life also access hospice care -Home Dialysis Improvement Act (HR 8875) and related policy concepts helping more patients consider electing home dialysis -Kidney Disease Education Expansion Act of 2026 (H.R. 9509) and related policy concepts to increase earlier upstream intervention to slow the progression of kidney disease, including screening and diagnosis -$77M in appropriations for HRSA Organ Transplant work in FY27 (funding to modernize the US transplant system and support living donors through reimbursement for living kidney donation-related costs) -$25M in appropriations for HHS in FY27 to support KidneyX (public-private partnership to catalyze innovation in kidney disease prevention, diagnosis, and treatment through a series of prize competitions) -Called for continued focus on modernizing the U.S. transplant system, including implementing the 2023 Securing the U.S. OPTN Act -Called for the creation of an Officer of Kidney Health and Transplantation within the immediate office of the secretary of HHS (to coordinate kidney health care, research, and data-related efforts across the numerous HHS agencies with a role in kidney health) -Urged HHS to ensure kidney health data remains accessible and complete, including advancing data-sharing, data standards, and interoperability -Encouraged CMMI to develop a subsequent kidney care focused model, building on the successes and lessons of the CKCC model -Asked questions about the adequacy of kidney patient access to specialized kidney and transplant care in MA plans -Endorsed the following bills: -Keeping Individuals with Dialysis Needs Equipped through Year-round (KIDNEY) Remote Monitoring Act (HR 8319) Provider Reimbursement Stability Act (HR 8163) -The Diabetes Foot Health Access and Modernization Act of 2026 (HR 7905/S 4070) -H-1Bs for Physicians and Healthcare Workforce Act (HR 7961) Living Organ Volunteer Engagement (LOVE) Act (HR 7581) -New Era of Preventing ESRD Act (HR 1518) -PKD Cures Act (HR 9169)
2026 · second_quarter · Health Issues
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Client expense: $1,200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Client expense: $1,240,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Activities to facilitate organ donation and transplantation, including the Honor our Living Donors Act (H.R. 628, S. 957); the Living Donor Protection Act (S.1552 and H.R. 4583); and legislation to clarify that organ donation surgery qualifies as a serious health condition for FMLA coverage (S. 1552, H.R. 4582). Implementation of P.L. 118-14, "Securing the U.S. Organ Procurement and Transplantation Network Act." Comments to FDA re: Proposal to Withdraw Approval of New Drug Application for TAVNEOS (Avacopan). Support for xenotransplantation. Initiatives to improve chronic kidney disease early detection and management. Implementation of the Advancing American Kidney Health Initiative. Support for telemedicine and telehealth access. The New Era of Preventing End-Stage Kidney Disease Act (H.R. 1518). Support for access to affordable, accessible health care, including Affordable Care Act enhanced premium tax credits.
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2026 · first_quarter · Health Issues
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medicare/Medicaid
H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Access to Genetic Counselor Services Act Living Donor Protection Act: H.R. 4582; H.R 4583; S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Enhanced Advance Premium Tax Credits (eAPTCs) Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 1 CMS-1830-P: End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40060 Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40058
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Health Issues
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
Client expense: $200,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Health Issues
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Client expense: $1,140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Client expense: $210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Activities to facilitate organ donation and transplantation, including the Honor our Living Donors Act (H.R. 628, S. 957); the Living Donor Protection Act (S.1552 and H.R. 4583); and legislation to clarify that organ donation surgery qualifies as a serious health condition for FMLA coverage (S. 1552, H.R. 4582). Implementation of P.L. 118-14, "Securing the U.S. Organ Procurement and Transplantation Network Act." Support for xenotransplantation. Comment letter in support for FDA approval of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). Implementation of the Advancing American Kidney Health Initiative. Support for telemedicine and telehealth access. The New Era of Preventing End-Stage Kidney Disease Act (H.R. 1518). Activities in support of access to affordable, accessible health care, including Affordable Care Act enhanced premium tax credits.
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2025 · first_quarter · Health Issues
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Medicare/Medicaid
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation impacting products approved under the Accelerated Approval pathway. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Medicare/Medicaid
H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
Activities to facilitate organ donation and transplantation, including the Honor our Living Donors Act (H.R. 628, S. 957); the Living Donor Protection Act (S.1552 and H.R. 4583); and legislation to clarify that organ donation surgery qualifies as a serious health condition for FMLA coverage (S. 1552, H.R. 4582). Request to require inclusion of phosphorus on nutrition labels. Implementation of P.L. 118-14, "Securing the U.S. Organ Procurement and Transplantation Network Act." Support for xenotransplantation. Implementation of the Advancing American Kidney Health Initiative. Support for telemedicine and telehealth access. The New Era of Preventing End-Stage Kidney Disease Act (H.R. 1518). Activities in support of access to affordable, accessible health care, including Affordable Care Act enhanced premium tax credits.
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2025 · fourth_quarter · Health Issues
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · fourth_quarter · Health Issues
Access to Genetic Counselor Services Act Living Donor Protection Act: H.R. 4582; H.R 4583; S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Enhanced Advance Premium Tax Credits (eAPTCs) Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 1 CMS-1830-P: End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40060 Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40058
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · third_quarter · Health Issues
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Medicare/Medicaid
H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
Access to Genetic Counselor Services Act Living Donor Protection Act: H.R. 4582; H.R 4583; S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Enhanced Advance Premium Tax Credits (eAPTCs) Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2730. H.R. 1 CMS-1830-P: End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40060 Proposed Local Coverage Determination (LCD) MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD ID: DL40058
Client expense: $156,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · third_quarter · Health Issues
Activities to facilitate organ donation and transplantation, including the Honor our Living Donors Act (H.R. 628, S. 957); the Living Donor Protection Act (S.1552 and H.R. 4583); and legislation to clarify that organ donation surgery qualifies as a serious health condition for FMLA coverage (S. 1552, H.R. 4582). Implementation of P.L. 118-14, "Securing the U.S. Organ Procurement and Transplantation Network Act." Implementation of the Advancing American Kidney Health Initiative. Support for telemedicine and telehealth access. The New Era of Preventing End-Stage Kidney Disease Act (H.R. 1518). Activities in support of access to affordable, accessible health care. Opposed changes to Affordable Care Act eligibility, access and affordability under the One Big Beautiful Bill (H.R. 1).
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2025 · third_quarter · Health Issues
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · second_quarter · Health Issues
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: Not reported · Firm income: $60,000
2025 · second_quarter · Medicare/Medicaid
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation impacting products approved under the Accelerated Approval pathway. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients. H.R.1, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Health Issues
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
Client expense: $200,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · first_quarter · Health Issues
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of priority review voucher program. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Medicare/Medicaid
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation impacting products approved under the Accelerated Approval pathway. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Medicare/Medicaid
H.R.1518 - New Era of Preventing End-Stage Kidney Disease Act
Client expense: Not reported · Firm income: $12,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Health Issues
H.R.1518 - New Era of Preventing End-Stage Kidney Disease Act
Client expense: Not reported · Firm income: $12,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Medical/Disease Research/Clinical Labs
H.R.1518 - New Era of Preventing End-Stage Kidney Disease Act
Client expense: Not reported · Firm income: $12,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Pharmacy
H.R.1518 - New Era of Preventing End-Stage Kidney Disease Act
Client expense: Not reported · Firm income: $12,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Taxation/Internal Revenue Code
H.R.1518 - New Era of Preventing End-Stage Kidney Disease Act
Client expense: Not reported · Firm income: $12,000
Government targets: HOUSE OF REPRESENTATIVES
2025 · first_quarter · Health Issues
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
Client expense: $160,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Republican |
| NY |
| Bennie G. Thompson | Democratic | MS |
| Bradley Scott Schneider | Democratic | IL |
| Brian K. Fitzpatrick | Republican | PA |
| Carol D. Miller | Republican | WV |
| Charles J. "Chuck" Fleischmann | Republican | TN |
| Chellie Pingree | Democratic | ME |
| Christopher H. Smith | Republican | NJ |
| Dan Crenshaw | Republican | TX |
| Danny K. Davis | Democratic | IL |
| Darren Soto | Democratic | FL |
| Deborah K. Ross | Democratic | NC |
| Don Bacon | Republican | NE |
| Donald G. Davis | Democratic | NC |
| Eleanor Holmes Norton | Democratic | DC |
| Eugene Simon Vindman | Democratic | VA |
| Gabe Vasquez | Democratic | NM |
| Glenn Ivey | Democratic | MD |
| Gwen Moore | Democratic | WI |
| Haley M. Stevens | Democratic | MI |
| Henry C. "Hank" Johnson, Jr. | Democratic | GA |
| Henry Cuellar | Democratic | TX |
| J. Luis Correa | Democratic | CA |
| Jack Bergman | Republican | MI |
| James P. McGovern | Democratic | MA |
| James R. Walkinshaw | Democratic | VA |
| Janelle S. Bynum | Democratic | OR |
| Jason Crow | Democratic | CO |
| Jay Obernolte | Republican | CA |
| Jefferson Van Drew | Republican | NJ |
| Jennifer A. Kiggans | Republican | VA |
| Jerrold Nadler | Democratic | NY |
| Joe Wilson | Republican | SC |
| Jonathan L. Jackson | Democratic | IL |
| Judy Chu | Democratic | CA |
| Julia Brownley | Democratic | CA |
| Kathy Castor | Democratic | FL |
| Mark Pocan | Democratic | WI |
| Michael Lawler | Republican | NY |
| Mike Carey | Republican | OH |
| Mike Flood | Republican | NE |
| Mike Levin | Democratic | CA |
| Mike Thompson | Democratic | CA |
| Neal P. Dunn | Republican | FL |
| Patrick Ryan | Democratic | NY |
| Paul Tonko | Democratic | NY |
| Rashida Tlaib | Democratic | MI |
| Robert Menendez | Democratic | NJ |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Sarah McBride | Democratic | DE |
| Scott H. Peters | Democratic | CA |
| Susie Lee | Democratic | NV |
| Ted Lieu | Democratic | CA |
| Terri A. Sewell | Democratic | AL |
| Thomas R. Suozzi | Democratic | NY |
| Troy Balderson | Republican | OH |
| Veronica Escobar | Democratic | TX |
| William R. Keating | Democratic | MA |
| Young Kim | Republican | CA |
| Yvette D. Clarke | Democratic | NY |
| Zoe Lofgren | Democratic | CA |
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE